OTTAWA, ON —For the fifth consecutive year, BioTalent Canada has been honoured with the distinction of being certified as a Great Place to Work®. This recognition is a testament to… Read More
Federal investment in Canada’s Immuno-Engineering and Biomanufacturing Hub projects will bolster domestic biotech sector, readiness to respond to future health threats When the next pandemic hits, Canada will be better… Read More
Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of… Read More
VANCOUVER, BC – Bold Therapeutics, the world leader in the development of novel metallotherapeutics, announced positive Phase 2 safety and efficacy results for the company’s lead asset BOLD-100 in the treatment… Read More
Company study investigating PEX010, Filament’s botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada VANCOUVER, BC – Filament Health Corp. (OTCQB:FLHLF) (Cboe CA:FH) (FSE:7QS) (“Filament” or the “Company”), a… Read More
